- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 13.11. | Zeo ScientifiX, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 13.11. | ZEO ScientifiX, Inc.: ZEO ScientifiX and Exotropin Join Forces to Launch a Solution to Address the Growing Unmet Need for Hair Loss | 139 | ACCESSWIRE | FORT LAUDERDALE, FL / ACCESSWIRE / November 13, 2024 / ZEO ScientifiX, Inc. ("ZEO" or the "Company") (OTCQB:ZEOX), a South Florida-based clinical-stage biopharmaceutical company, announced it has partnered... ► Artikel lesen | |
| 15.10. | Zeo ScientifiX, Inc. - 8-K, Current Report | 4 | SEC Filings | ||
| 15.10. | Zeo ScientifiX, Inc.: ZEO ScientifiX, a Leading South Florida Biotechnology Company, Launches Regenerative Medicine Educational Series for Physicians | 167 | ACCESSWIRE | Events Hosted By ZEO ScientifiX Offer Providers Practical Business Tools Along With Science And Research Insights FORT LAUDERDALE, FL / ACCESSWIRE / October 15, 2024 / ZEO ScientifiX, Inc. ("ZEO" or... ► Artikel lesen | |
| 01.10. | Zeo ScientifiX, Inc.: ZEO ScientifiX Partners with National Provider of Healthcare Services | 170 | ACCESSWIRE | Physicians Group, LLC's Network Of Clinics And Diverse Patient Population Will Provide ZEO With Exclusive Research-Based OpportunitiesFORT LAUDERDALE, FL / ACCESSWIRE / October 1, 2024 / ZEO ScientifiX... ► Artikel lesen | |
| 30.09. | Zeo ScientifiX, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 24.09. | Zeo ScientifiX, Inc.: ZEO ScientifiX is Moving Toward Its Goal of Transforming Healthcare Through Leading-Edge Research | 239 | ACCESSWIRE | South Florida Biotech Company Seeks To Expand Its Research Program Into Phase 2 Clinical TrialsFORT LAUDERDALE, FL / ACCESSWIRE / September 24, 2024 / ZEO ScientifiX, Inc. ("ZEO" or the "Company") (OTCQB:ZEOX)... ► Artikel lesen | |
| ZEO SCIENTIFIX Aktie jetzt für 0€ handeln | |||||
| 20.09. | Zeo ScientifiX, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 16.09. | Zeo ScientifiX, Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 07.08. | Zeo ScientifiX, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 12.07. | Zeo ScientifiX, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 14.06. | Zeo ScientifiX, Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 03.06. | Zeo ScientifiX, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 04.03. | Organicell Regenerative Medicine, Inc. Rebranding to ZEO ScientifiX, Inc. | 518 | ACCESSWIRE | Leading Therapeutics Research Company Begins New EraCommon Stock to trade on OTCQB under the symbol "ZEOX" commencing March 5, 2024FORT LAUDERDALE, FL / ACCESSWIRE / March 4, 2024 / ZEO ScientifiX,... ► Artikel lesen | |
| 27.11.23 | Organicell Regenerative Medicine, Inc. Announces 1-for-200 Reverse Stock Split | 504 | ACCESSWIRE | FORT LAUDERDALE, FL / ACCESSWIRE / November 27, 2023 / Organicell Regenerative Medicine Inc, (OTCQB:OCEL) ("Organicell" or the "Company"), today announced that it is implementing a 1-for-200 Reverse... ► Artikel lesen |
15 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| ADMA BIOLOGICS | 21,370 | 0,00 % | Adma Biologics Aktie: Erholung nach starkem Kursrückgang | ||
| RECURSION PHARMACEUTICALS | 6,040 | 0,00 % | Recursion Pharmaceuticals, Inc.: Recursion and Exscientia, two leaders in the AI drug discovery space, have officially combined to advance the industrialization of drug discovery | Recursion unveils post-combination technology-enabled portfolio with more than 10 clinical and preclinical programs, 10 advanced discovery programs, and more than 10 partnered programsPlatform will... ► Artikel lesen | |
| EVOTEC | 9,845 | -0,61 % | Märkte am Morgen: Bitcoin, Talanx, Evotec, ASML, Infineon, Domino's Pizza, Palantir | Der DAX sich gestern von seiner starken Seite präsentiert und kräftig zugelegt. Am Ende ging der Leitindex 1,37 Prozent höher bei 19.263 Punkten aus dem Handel. Heute muss er mit unterschiedlichen Vorgabe... ► Artikel lesen | |
| QIAGEN | 40,210 | +3,53 % | Neue 6,00% Aktienanleihe mit Barriere auf QIAGEN in Zeichnung | München (www.anleihencheck.de) - Die Experten vom Zertifikate-Team der Bank Vontobel Europe AG bieten eine neue Aktienanleihe (ISIN DE000VC7RDU1/ WKN VC7RDU) mit Barriere auf die Aktie von QIAGEN (ISIN... ► Artikel lesen | |
| QUANTUM-SI | 1,400 | 0,00 % | Quantum-Si Inc - 8-K, Current Report | ||
| 89BIO | 7,980 | 0,00 % | 89bio, Inc.: 89bio Presents New Analyses Evaluating Pegozafermin and Potential Benefit of Non-Invasive Tests from the ENLIVEN Phase 2b Trial in MASH Patients at AASLD The Liver Meeting 2024 | SAN FRANCISCO, Nov. 15, 2024 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for... ► Artikel lesen | |
| LONGBOARD PHARMACEUTICALS | 59,76 | 0,00 % | Longboard Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Corporate Updates | LA JOLLA, Calif.--(BUSINESS WIRE)--Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological... ► Artikel lesen | |
| RELAY THERAPEUTICS | 4,660 | 0,00 % | Aktie von Relay Therapeutics erreicht 52-Wochen-Tief bei 5,59 US-Dollar | ||
| STRUCTURE THERAPEUTICS | 32,710 | 0,00 % | Structure Therapeutics reports Q3 results | ||
| SPRINGWORKS THERAPEUTICS | 37,440 | 0,00 % | SpringWorks started at outperform by Evercore ahead of FDA decision | ||
| 4D MOLECULAR THERAPEUTICS | 8,410 | 0,00 % | Analyst Expectations For 4D Molecular Therapeutics' Future | ||
| DYNE THERAPEUTICS | 30,000 | 0,00 % | Wissenschaftliche Leiterin von Dyne Therapeutics verkauft Aktien im Wert von 80.539 US-Dollar | ||
| CULLINAN THERAPEUTICS | 12,580 | 0,00 % | Cullinan Therapeutics, Inc.: Cullinan Therapeutics Announces Preclinical Data for CLN-978, a CD19-directed T Cell Engager, to be Presented at ACR Convergence 2024 | Cullinan will present new in vitro preclinical data that provide further strong rationale for broad clinical development of CLN-978 in autoimmune diseases Cullinan will share details of global Phase... ► Artikel lesen | |
| VIR BIOTECHNOLOGY | 6,740 | 0,00 % | Needham & Company LLC Reaffirms Buy Rating for Vir Biotechnology (NASDAQ:VIR) | ||
| VERVE THERAPEUTICS | 4,550 | 0,00 % | Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) | BOSTON, Nov. 01, 2024 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage company developing a new class of genetic medicines for cardiovascular disease, today announced that on October 31, 2024... ► Artikel lesen |
ZEO SCIENTIFIX INC gehört der Branche Biotechnologie an.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ZEO SCIENTIFIX INC finden Sie auf Wallstreet Online.
